Back to today’s briefing

Story perspectives

Biogen Invests $2 Billion to Enhance NC Manufacturing

7/22/2025

45 9

Summary

Story summary

Biogen Inc. is set to bolster its North Carolina manufacturing facilities in Research Triangle Park with a hefty $2 billion investment. This move, part of a $10 billion commitment over three decades, will boost production of vital medications, including antisense oligonucleotides, while integrating AI-driven automation to safeguard against rising tariff challenges.

History

Historical Context

In 1996, the FDA approved the first antisense oligonucleotide drug, revolutionizing biotechnology. Biogen Inc.'s recent $2 billion investment in North Carolina aims to enhance production capabilities for these drugs. This move reflects a broader trend of pharmaceutical companies adapting to economic pressures, potentially increasing drug accessibility and fostering innovation in biomanufacturing processes in the coming years.

1 of 2

Story summary

Biogen Inc. is set to bolster its North Carolina manufacturing facilities in Research Triangle Park with a hefty $2 billion investment. This move, part of a $10 billion commitment over three decades, will boost production of vital medications, including antisense oligonucleotides, while integrating AI-driven automation to safeguard against rising tariff challenges.

1 / 2